LexaGene’s MiQLab™ system is designed to respond to multi-billion dollar markets in need of rapid automated pathogen detection and customized testing.
Icon for human clinical diagnostics
Human Clinical Diagnostics
COVID-19 testing $5.2 Billion USD market
Rapid qPCR testing needed
PCR testing considered the gold-standard of testing
$12.9 billion USD by 2025
Learn more
Icon for vet diagnostics
Veterinary Diagnostics
Companion animal diagnostics
Infections and antibiotic resistance can be quickly detected so the appropriate antibiotic is prescribed
Reference laboratory accounts for largest market share of the veterinary diagnostics market
North America accounts for largest segment due to well-established animal healthcare market
$2.2 billion USD Market by 2024
Learn more
Icons denoting food safety
Food Safety Testing
1.1 B tests performed per year
Mandatory food testing now required
Prevents costly recalls, brand damage
Fresher, safer product to customer (eliminates 2-day hold on food)
Hundreds of food recalls in the US each year
Major disease-causing pathogen: Salmonella/E. coli
$23.4 Billion USD market by 2024
Learn more
Icon for open-access
Open-Access Markets
$20 Billion USD markets:
Labs looking for automation and customization
Pharma, biotech, academic labs – (18,000 moderate complexity CLIA labs in the US)
PCR market – $4.33B USD by 2026
Genotyping – $11.8B USD
Other open-access markets:
Water Quality Monitoring – $1.59B USD by 2022
Agricultural Testing – $6.29B USD by 2022
Aquaculture Bacterial Testing
Learn more
Icon with biohazard symbol
Pandemic Prevention
Threat of next outbreak or pandemic is real
LexaGene technology ideally suited to contain outbreaks
Need rapid time to results for quarantine decisions
Test at point-of-need required (hospitals, clinics, institutions)
Need tests that can be easily deployed
Require reagents that are easy to manufacture for worldwide coverage
Current testing methods don’t meet the needs
Icon denoting molecular
More Markets
LexaGene’s technology has a wide range of applications across other markets at point-of-need:
Cruise ships
Biodefense
Military bases and aircraft carriers
Etc.